Prospective students          Students           Collaborations    
  •   Chimeric antigen receptor (CAR)-expressing T cells for cancer immunotherapy (Adapted from Heczey A. et al., 2013, Discov Med and Kochenderfer JN. et al., 2013, Nat. Rev. Clin. Oncol)

  •   Cytotoxicity of AC133-specific CAR T cells in vitro

  •   The interaction between glioma cells and CD8+ T cells

Lab of T Cell Engineering 
   About Lab ح Lab Members ح Publications ح News ح Join Us

Research Interests:

Recent clinical trials have shown that T cell therapy, which makes use of the host's own immune system, can cure some cancer patients, such as CD19-specific chimeric antigen receptor (CAR) redirected T cell therapy for B-cell malignancies, adoptive transfer of tumor infiltrating lymphocytes (TILs) for melanoma, cholangiocarcinoma and cervical cancer. However, only a small population of patients now can benefit from this kind of immunotherapy. Our lab is interested in developing engineered tumor-specific T cells for treating more cancer patients.

Current projects include:

1:Targeting cancer stem cells (CSCs) by CAR T cells for the treatment of cancer patients.

2:Combination of CRISPR/cas9 system and CAR technology for producing activated tumor-specific CAR T cells.


Building 6, No. 99 Haike Road, Pudong, Shanghai, 201210 

  Copyright © 2015 Shanghai Institute for Advanced
Immunochemical Studies Institute of ShanghaiTech All rights reserved